MetCure Therapeutics LLC — Department of Health and Human Services STTR Phase I: 102

Description

DESCRIPTION provided by applicant Castration Resistant Prostate Cancer Castration resistant prostate cancer CRPC directly contributes to patient mortality It is imperative to develop new and effective adjunct therapy to enhance the response of CRPC to hormonal therapy Recently we developed ProFineTM a proprietary formula consisting of bioactive flavonoids enriched in pomegranate fruit and demonstrated its potent anti cancer activity in CRPC cells In this Phase I STTR application we hypothesize that ProFineTM potently co targets AR and Akt signaling thereby activating apoptosis in CRPC cells and sensitizing them to androgen deprivation therapy ADT Two Aims are proposed Aim will determine the mechanism of action of ProFineTM in CRPC cells specifically how ProFineTM inhibits androgen receptor signaling Aim will evaluate the efficacy of ProFineTM in enhancing enzalutamide hormonal therapy in an orthotopic model of CRPC Accomplishment of the proposed studies will provide solid evidence for future patent application and a Phase II STTR application PUBLIC HEALTH RELEVANCE American Cancer Society estimated that new cases will be diagnosed with prostate cancer PCa in and patients will die mostly from castration resistant disease CRPC It is imperative to develop safe efficacious and cost effective adjunct therapy to enhance the response of CPRC to standard therapies In this Phase I STTR application we will develop ProFineTM a pomegranate derived flavonoid formula as an effective adjunct treatment to enzalutamide therapy in CRPC It is expected that as a dietary supplement ProFineTM can be rapidly commercialized and approved for clinical trials This proposal has profound impact due to its immediate potentia l in treating a lethal disease reducing cancer morbidity and improving healthcare in the United States and globally